Top

Tumor Biology

Published in:

01-10-2013 | Research Article

microRNA and transcription factor mediated regulatory network for ovarian cancer

Regulatory network of ovarian cancer

Authors: Huanchun Ying, Jing Lv, Tianshu Ying, Jun Li, Qing Yang, Yuan Ma

Published in: Tumor Biology | Issue 5/2013

Abstract

A better understanding on the regulatory interactions of microRNA (miRNA) target genes and transcription factor (TF) target genes in ovarian cancer may be conducive for developing early diagnosis strategy. Thus, gene expression data and miRNA expression data were downloaded from The Cancer Genome Atlas in this study. Differentially expressed genes and miRNAs were selected out with t test, and Gene Ontology enrichment analysis was performed with DAVID tools. Regulatory interactions were retrieved from miRTarBase, TRED, and TRANSFAC, and then networks for miRNA target genes and TF target genes were constructed to globally present the mechanisms. As a result, a total of 1,939 differentially expressed genes were identified, and they were enriched in 28 functions, among which cell cycle was affected to the most degree. Besides, 213 differentially expressed miRNAs were identified. Two regulatory networks for miRNA target genes and TF target genes were established and then both were combined, in which E2F transcription factor 1, cyclin-dependent kinase inhibitor 1A, cyclin E1, and miR-16 were the hub genes. These genes may be potential biomarkers for ovarian cancer.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49. doi:10.3322/caac.20006caac.20006.CrossRefPubMed

Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295–303. doi:10.1001/jama.2011.766305/22/229.CrossRefPubMed

Chou J, Werb Z. MicroRNAs play a big role in regulating ovarian cancer-associated fibroblasts and the tumor microenvironment. Cancer Discov. 2012;2(12):1078–80. doi:10.1158/2159-8290.PubMedCentralCrossRefPubMed

van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol. 2010;42(8):1282–90. doi:10.1016/j.CrossRefPubMed

Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013;23(2):186–99. doi:10.1016/j.ccr.2012.12.020.PubMedCentralCrossRefPubMed

Crijns AP, Fehrmann RS, de Jong S, Gerbens F, Meersma GJ, Klip HG, et al. Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med. 2009;6(2):e24. doi:10.1371/journal.pmed.100002408-PLME-RA-1271.CrossRefPubMed

Llaurado M, Abal M, Castellvi J, Cabrera S, Gil-Moreno A, Perez-Benavente A, et al. ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells. Int J Cancer. 2012;130(7):1532–43. doi:10.1002/ijc.26148.CrossRefPubMed

Bendoraite A, Knouf EC, Garg KS, Parkin RK, Kroh EM, O’Briant KC, et al. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol. 2010;116(1):117–25. doi:10.1016/j.PubMedCentralCrossRefPubMed

Morgan R, Plowright L, Harrington KJ, Michael A, Pandha HS. Targeting HOX and PBX transcription factors in ovarian cancer. BMC Cancer. 2010;10:89. doi:10.1186/1471-2407-10-89.PubMedCentralCrossRefPubMed

10.

Kulasingam V, Pavlou MP, Diamandis EP. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer. 2010;10(5):371–8. doi:10.1038/nrc2831nrc2831.CrossRefPubMed

11.

Trevino LS, Giles JR, Wang W, Urick ME, Johnson PA. Gene expression profiling reveals differentially expressed genes in ovarian cancer of the hen: support for oviductal origin? Horm Cancer. 2010;1(4):177–86. doi:10.1007/s12672-010-0024-8.CrossRefPubMed

12.

Wu J, Xie X, Liu Y, He J, Benitez R, Buckanovich RJ, et al. Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS. J Proteome Res. 2012;11(9):4541–52. doi:10.1021/pr300330z.CrossRefPubMed

13.

Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–8. doi:10.1038/nature07385nature07385.

14.

Yao C, Li H, Shen X, He Z, He L, Guo Z. Reproducibility and concordance of differential DNA methylation and gene expression in cancer. PLoS One. 2012;7(1):e29686. doi:10.1371/journal.pone.0029686PONE-D-11-16562.PubMedCentralCrossRefPubMed

15.

Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statist Soc Series B (Methodological). 1995;57:289–300.

16.

Huangda W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57. doi:10.1038/nprot.2008.211.CrossRef

17.

Fu J, Tang W, Du P, Wang G, Chen W, Li J, et al. Identifying microRNA-mRNA regulatory network in colorectal cancer by a combination of expression profile and bioinformatics analysis. BMC Syst Biol. 2012;6:68. doi:10.1186/1752-0509-6-681752-0509-6-68.PubMedCentralCrossRefPubMed

18.

Yu J, Cai X, He J, Zhao W, Wang Q, Liu B. Microarray-based analysis of gene regulation by transcription factors and microRNAs in glioma. Neurol Sci. 2012. doi:10.1007/s10072-012-1228-1.

19.

Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G, et al. Clinical relevance of E2F family members in ovarian cancer—an evaluation in a training set of 77 patients. Clin Cancer Res. 2007;13(1):144–51. doi:10.1158/1078-0432.CCR-06-0780.CrossRefPubMed

20.

Valle BL, D’Souza T, Becker KG, Wood III WH, Zhang Y, Wersto RP, et al. Non-steroidal anti-inflammatory drugs decrease E2F1 expression and inhibit cell growth in ovarian cancer cells. PLoS One. 2013;8(4):e61836.PubMedCentralCrossRefPubMed

21.

Wu L, Timmers C, Maiti B, Saavedra HI, Sang L, Chong GT, et al. The E2F1-3 transcription factors are essential for cellular proliferation. Nature. 2001;414(6862):457–62. doi:10.1038/3510659335106593.CrossRefPubMed

22.

Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature. 1993;365(6444):349–52. doi:10.1038/365349a0.CrossRefPubMed

23.

de Resende MF, Vieira S, Chinen LTD, Chiappelli F, da Fonseca FP, Guimarães GC, et al. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer. J Transl Med. 2013;11(1):1–9.CrossRef

24.

Zhou B, Yuan T, Liu M, Liu H, Xie J, Shen Y, et al. Overexpression of the structural maintenance of chromosome 4 protein is associated with tumor de-differentiation, advanced stage and vascular invasion of primary liver cancer. Oncol Rep. 2012;28(4):1263–8.PubMed

25.

Uchida F, Uzawa K, Kasamatsu A, Takatori H, Sakamoto Y, Ogawara K, et al. Overexpression of cell cycle regulator CDCA3 promotes oral cancer progression by enhancing cell proliferation with prevention of G1 phase arrest. BMC Cancer. 2012;12(1):321.PubMedCentralCrossRefPubMed

26.

Trompeter HI, Abbad H, Iwaniuk KM, Hafner M, Renwick N, Tuschl T, et al. MicroRNAs MiR-17, MiR-20a, and MiR-106b act in concert to modulate E2F activity on cell cycle arrest during neuronal lineage differentiation of USSC. PLoS One. 2011;6(1):e16138. doi:10.1371/journal.pone.0016138.PubMedCentralCrossRefPubMed

27.

Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, Major F, et al. An E2F/miR-20a autoregulatory feedback loop. J Biol Chem. 2007;282(4):2135–43. doi:10.1074/jbc.M608939200.CrossRefPubMed

28.

LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997;11(7):847–62.CrossRefPubMed

29.

Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci U S A. 2000;97(16):9042–6. doi:10.1073/pnas.PubMedCentralCrossRefPubMed

30.

Hui L, Zatloukal K, Scheuch H, Stepniak E, Wagner EF. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest. 2008;118(12):3943–53. doi:10.1172/JCI3715637156.PubMedCentralCrossRefPubMed

31.

Yu JH, Zhu B-M, Wickre M, Riedlinger G, Chen W, Hosui A, et al. The transcription factors STAT5A and STAT5B negatively regulate cell proliferation through the activation of Cdkn2b and Cdkn1a expression. Hepatology (Baltimore, Md). 2010;52(5):1808.CrossRef

32.

Petrocca F, Vecchione A, Croce CM. Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res. 2008;68(20):8191–4. doi:10.1158/0008-5472.CrossRefPubMed

33.

Gibcus JH, Kroesen BJ, Koster R, Halsema N, de Jong D, de Jong S, et al. MiR–17/106b seed family regulates p21 in Hodgkin’s lymphoma. J Pathol. 2011;225(4):609–17.CrossRefPubMed

34.

Wang F, Fu XD, Zhou Y, Zhang Y. Down-regulation of the cyclin E1 oncogene expression by microRNA-16-1 induces cell cycle arrest in human cancer cells. BMB Rep. 2009;42(11):725–30.CrossRefPubMed

35.

Guo X, Hartley RS. Hur contributes to cyclin E1 deregulation in MCF-7 breast cancer cells. Cancer Res. 2006;66(16):7948–56. doi:10.1158/0008-5472.CAN-05-4362.CrossRefPubMed

36.

Ohtani K, DeGregori J, Nevins JR. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci U S A. 1995;92(26):12146–50.PubMedCentralCrossRefPubMed

37.

Bhattacharya R, Nicoloso M, Arvizo R, Wang E, Cortez A, Rossi S, et al. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 2009;69(23):9090–5.PubMedCentralCrossRefPubMed

38.

Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, et al. miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res. 2008;36(16):5391–404.PubMedCentralCrossRefPubMed

Title: microRNA and transcription factor mediated regulatory network for ovarian cancer
Regulatory network of ovarian cancer
Authors: Huanchun Ying
Jing Lv
Tianshu Ying
Jun Li
Qing Yang
Yuan Ma
Publication date: 01-10-2013
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 5/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-0892-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2013

MicroRNA-200a/b influenced the therapeutic effects of curcumin in hepatocellular carcinoma (HCC) cells

Inhibition of mTOR and HIF pathways diminishes chondro-osteogenesis and cell proliferation in chondroblastoma

Target expression of Staphylococcus enterotoxin A from an oncolytic adenovirus suppresses mouse bladder tumor growth and recruits CD3+ T cell

Interactional expression of netrin-1 and its dependence receptor UNC5B in prostate carcinoma

Associations between three XRCC1 polymorphisms and glioma risk: a meta-analysis

Association between glutathione S-transferase T1 null genotype and risk of myelodysplastic syndromes: a comprehensive meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer